RALEIGH, N.C., April 5, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced that it has initiated a Phase Ib clinical study for DB959, its PPAR (peroxisome proliferator activated receptor) delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes. “The promising and exciting results from the Phase Ia study and the pre-clinical studies prompted us to initiate this clinical study as soon as possible,” said Mary Kay Delmedico, Ph.D., Director of Drug Development and Portfolio Management at DARA. This study’s main objectives are to determine the safety and pharmacokinetics of multiple ascending oral doses of DB959Na in both male and female subjects. The Company expects to report the results of the study during Q3 2011.
